Literature DB >> 28389802

The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-matched analysis.

Sung Hwan Lee1,2, Ho Kyoung Hwang1,2, Chang Moo Kang3,4, Woo Jung Lee1,2.   

Abstract

BACKGROUND: This study aimed to identify that Yonsei criteria (YC) can be regarded as a preoperative clinical parameter to predict biological behavior of the left-sided pancreatic cancer.
METHODS: Between June 2007 and December 2014, 135 patients who underwent minimally invasive (MIS) or open distal pancreatectomy for left-sided pancreatic cancer were enrolled in this study consecutively. Perioperative short-term and long-term oncologic outcomes were analyzed according to the YC retrospectively.
RESULTS: Fifty-four and 81 patients did and did not meet the YC, respectively. Short-term oncologic outcomes were favorable among those meeting the YC even after propensity score matching. Patients within the YC also had better disease-free and disease-specific overall survival (p < 0.05). In analysis for receiver operating characteristic curve, area under curve of CA19-9 was satisfactory only within YC group. Multivariate analysis for disease-free survival identified the YC as a strong independent prognostic factor (p < 0.05). In preoperative clinical setting, patients' survival was clearly different based on following clinical groups, such as within YC, beyond YC, and unresectable.
CONCLUSIONS: Preoperative CT-based determined YC can predict excellent short-term and long-term oncologic outcomes. YC might have a potential role as a preoperative clinical staging for left-sided pancreatic cancer. External validations of YC based on multicenter cohorts are mandatory to confirm this oncologic significance of YC.

Entities:  

Keywords:  Disease-free survival; Pancreatic cancer; Selection criteria

Mesh:

Year:  2017        PMID: 28389802     DOI: 10.1007/s00464-017-5529-6

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  21 in total

1.  Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer.

Authors:  Chang Moo Kang; Yong Eun Chung; Jeong Youp Park; Jin Sil Sung; Ho Kyoung Hwang; Hye Jin Choi; Hyunki Kim; Si Young Song; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2011-12-20       Impact factor: 3.452

2.  Current surgical management of pancreatic cancer.

Authors:  Charles B Kim; Shuja Ahmed; Eddy C Hsueh
Journal:  J Gastrointest Oncol       Date:  2011-09

Review 3.  New biomarkers and targets in pancreatic cancer and their application to treatment.

Authors:  Eithne Costello; William Greenhalf; John P Neoptolemos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-26       Impact factor: 46.802

4.  Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.

Authors:  Emily Chan; Jordan Berlin
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

Review 5.  Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives.

Authors:  Chang Moo Kang; Sung Hwan Lee; Woo Jung Lee
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 6.  Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.

Authors:  V Heinemann; M Haas; S Boeck
Journal:  Ann Oncol       Date:  2013-07-12       Impact factor: 32.976

7.  Multimedia article. Laparoscopic modified anterior RAMPS in well-selected left-sided pancreatic cancer: technical feasibility and interim results.

Authors:  Sung Hoon Choi; Chang Moo Kang; Woo Jung Lee; Hoon Sang Chi
Journal:  Surg Endosc       Date:  2011-02-07       Impact factor: 4.584

Review 8.  Current staging systems for pancreatic cancer.

Authors:  Betsy L Appel; Parag Tolat; Douglas B Evans; Susan Tsai
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

9.  Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.

Authors:  Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

10.  A five-year survivor without recurrence following robotic anterior radical antegrade modular pancreatosplenectomy for a well-selected left-sided pancreatic cancer.

Authors:  Dai Hoon Han; Chang Moo Kang; Woo Jung Lee; Hoon Sang Chi
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

View more
  4 in total

1.  Minimally invasive vs open pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Juwan Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  World J Gastrointest Oncol       Date:  2020-10-15

2.  Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.

Authors:  Ke Chen; Yu Pan; Chao-Jie Huang; Qi-Long Chen; Ren-Chao Zhang; Miao-Zun Zhang; Guan-Yu Wang; Xian-Fa Wang; Yi-Ping Mou; Jia-Fei Yan
Journal:  BMC Cancer       Date:  2021-04-09       Impact factor: 4.430

3.  Yonsei criteria: a clinical reflection of stage I left-sided pancreatic cancer.

Authors:  Jae Uk Chong; Sung Hyun Kim; Ho Kyoung Hwang; Chang Moo Kang; Woo Jung Lee
Journal:  Oncotarget       Date:  2017-11-28

Review 4.  Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma?

Authors:  Chang Moo Kang; Woo Jung Lee
Journal:  Cancers (Basel)       Date:  2020-11-18       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.